(Q34918948)

English

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

5

object named as

Nyla A Heerema

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

16

object named as

Kristie A Blum

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jeffrey A Jones

9

object named as

Jeffrey A Jones

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Robert A Baiocchi

12

object named as

Robert A Baiocchi

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Steven M Devine

15

object named as

Steven M Devine

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gerard Lozanski

3

object named as

Gerard Lozanski

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

4

object named as

Weiqiang Zhao

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

13

object named as

Kami J Maddocks

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

7

object named as

Veena A Nagar

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jonathon B Cohen

1

object named as

Jonathon B Cohen

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Pierluigi Porcu

10

object named as

Pierluigi Porcu

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Susan M Geyer

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Nathan C Hall

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Jessica A Hemminger

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Beth A Christian

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Joseph M Flynn

14

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

27 February 2014

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

120

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

1677-1685

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4291121

8 July 2018

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

Report on the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8–9 April 2010

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

MYC rearrangements are useful for predicting outcomes following rituximab and chemotherapy: multicenter analysis of Japanese patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28642

21 January 2018

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/24578014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.28642

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34918948&oldid=1858788002"